Hemlibra 30mg Injection: Effective Treatment for Hemophilia

Hemlibra 30mg Injection

Active constituent: Emicizumab.

Class of medication: Monoclonal antibodies.

Uses:

• Treatment of patients with haemophilia A who have developed factor VIII inhibitors.
• Treatment of severe haemophilia A who have not developed factor VIII inhibitors (the FVIII blood level is less than 1%).

Therapeutic effects:

• Binds to activated factor IX and factor X to restore function to the coagulation cascade and promote hemostasis.
• Restores the function of missing activated factor VIII, which is needed for effective blood clotting.
• Its structure differs from factor VIII; therefore, the medicine is unaffected by factor VIII inhibitors.

Interaction with other drugs:

• Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products.
• Certain medications interact with Hemlibra 30mg Injection and reduce its effectiveness by causing undesirable side effects.

Storage:

• Store in a refrigerator (2°C to 8°C).
• Do not freeze.
• Protect the medicine from light and excessive moisture.
• Keep the medicine out of reach of children and pets.
• If you missed the dosing schedule, inform your healthcare professional immediately and reschedule.

Administration:

• Hemlibra 30mg Injection will be given by injection under the skin (subcutaneous).
• Your doctor or nurse or other healthcare professional will show you how to inject the medicine.
• Do not try to administer the medicine if you are not well-trained.
• The recommended places to give an injection are the front of the waist (lower abdomen), upper outer arms, or the front of the thighs.
• For each injection, use a different area of the body than the one you used last time.

Safety advices:

• Pregnancy: do not take Hemlibra 30mg Injection if you are pregnant because this may harm the unborn baby.
• Breastfeeding: breastfeeding is not recommended in patients taking Hemlibra 30mg Injection because the medicine passes into the breast milk in small amounts and may harm your baby.
• Lungs: it is unknown whether Hemlibra 30mg Injection can be used in patients with lung disorders.
• Liver: it is safe to administer Hemlibra 30mg Injection in patients with liver problems. No dose adjustments are needed for mild to moderate impairment.
• Alcohol: it is unknown whether it is safe to consume alcohol with Hemlibra 30mg Injection.
• Driving: Hemlibra 30mg Injection does not affect your ability to drive and operate heavy machinery.

Side effects:

• Common: injection site reactions, joint pain, headache.
• Serious: heart problems, muscle cramps and pain, blood clot, bleeding, destruction of red blood cells.

Word of advice:

• Use a different body area each time you give yourself a shot. Keep track of where you give each shot to make sure you rotate body areas.
• Do not inject into skin areas that are tender, red, bruised, hard, or not intact, or into areas with moles or scars.
• Use a new needle and syringe each time you inject your medicine.
• Women should use an effective form of birth control to keep from getting pregnant.

FAQs:

• Q 1. Can Hemlibra 30mg Injection be self-administered at home? Yes, Hemlibra 30mg Injection can be self-administered at home after proper training and instructions from a healthcare professional. However, the decision to self-administer should be made in consultation with the healthcare team.
• Q 2. Can Hemlibra 30mg Injection be used in pediatric patients with haemophilia? Yes, Hemlibra 30mg Injection is approved for use in pediatric patients with haemophilia A. The dosage and administration may vary depending on the age and weight of the child, and it should be prescribed and monitored by a healthcare professional.
• Q 3. Is Hemlibra 30mg Injection suitable for all types of haemophilia? Hemlibra 30mg Injection is specifically designed for the treatment of haemophilia A, which is caused by a deficiency of clotting factor VIII. It is not intended for other types of haemophilia, such as haemophilia B.

Fact box:

• Molecule name: Emicizumab.
• Therapeutic class: Antihemophilic agent.
• Pharmacological class: Bispecific monoclonal antibody.
• Indications: Haemophilia A.

Tags: diabetes, insulin, hemoglobin, medical, healthcare, medication, injection, drug, treatment, medicine